[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100517710":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":40,"responsibleParty":59,"collaborators":10,"id":62,"slug":10,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":10,"eligibilityCriteria":66,"healthyVolunteers":63,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":73,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":80,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Fujian Provincial Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CVVHD",null,"Continuous Veno-Venous Hemosdialysis",[13],"Procedure: CVVHD",{"label":15,"type":10,"description":16,"interventionNames":17},"CVVH","Continuous Veno-Venous Hemofiltration",[18],"Procedure: CVVH",[20,24],{"type":21,"name":15,"description":22,"armGroupLabels":23,"otherNames":10},"PROCEDURE","CVVH therapy",[15],{"type":21,"name":9,"description":25,"armGroupLabels":26,"otherNames":10},"CVVHD therapy",[9],[28],{"name":29,"affiliation":5,"role":30},"Han Chen, Ph.D., M.D.","PRINCIPAL_INVESTIGATOR",[32,36],{"name":29,"role":33,"phone":34,"phoneExt":10,"email":35},"CONTACT","+86 591 88217010","hanchen.cn@icloud.com",{"name":37,"role":33,"phone":38,"phoneExt":10,"email":39},"Wan-Li Yan, M.D.","+86 591 88217011","1727731759@qq.com",[41],{"facility":5,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Fuzhou","Fujian","350001","China","CN",{"type":49,"coordinates":50},"Point",[51,52],119.30611,26.06139,{"lat":52,"lon":51},[55],{"name":56,"role":33,"phone":57,"phoneExt":10,"email":58},"Fa-Yang Lian, M.D.","+86 591 88216023","flsykyk@163.com",{"type":30,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Han Chen","Deputy chief physician","100517710",false,"NCT06021080","Effects of Different Continuous Renal Replacement Therapy Patterns on Ionized Calcium in Patients With Citrate Anticoagulants Using Calcium-containing Replacement Solutions","Inclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Receiving citrate anticoagulation;\n3. Obtain Informed consent from patients or next of kin.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. Allergic to citrate anticoagulants;\n3. Severe liver dysfunction (total bilirubin levels exceeding two times the normal range);\n4. Hypoxemia (PaO2 \\\u003C 60 mmHg);\n5. Inadequate tissue perfusion (blood pressure \\\u003C 90\u002F60 mmHg despite high doses of vasoactive agents);\n6. Hyperlactatemia (lactate\\> 4 mmol\u002FL);\n7. Hypernatremia;\n8. Estimated length of hospital stay \\\u003C 48h;\n9. Participated in other studies.","ALL","18 Years","100 Years",{"count":71,"type":72},30,"ESTIMATED","1 Month","OBSERVATIONAL","It is unclear whether different modes of continuous renal replacement therapy (CRRT) impact post-filter ionized calcium concentrations during regional citrate anticoagulation (RCA) when using calcium-containing replacement fluid.\n\nThis prospective, single-center, observational cohort study will screen all patients receiving CRRT for eligibility. General clinical information will be collected before commencing CRRT treatment. Patients will be randomly assigned to either the veno-venous hemofiltration (CVVH) or continuous veno-venous hemodialysis (CVVHD) group and switch to the alternative mode in the subsequent treatment session. Pre-filter and post-filter ionized calcium, systemic total and ionized calcium, and effluent total and ionized calcium will be measured 2 hours after the initiation of CRRT. Electrolyte levels, arterial blood gases, hourly citrate dose, and total citrate dose will be recorded every 6 hours until the end of CRRT. The primary outcome is the difference in ionized calcium concentrations at each site over time between the two modes.",[77,78,79],"Renal Injury","Regional Citrate Anticoagulation","Continuous Renal Replacement Therapy",[77,81,82],"Regional citrate anticoagulation","Continuous renal replacement therapy","2025-08-05",{"date":85,"type":86},"2025-08-06","ACTUAL",{"date":88,"type":86},"2023-10-09",{"date":90,"type":72},"2026-12-09",{"name":5,"class":6},1]